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a  b  s  t  r  a  c  t
In recent years, extreme attention has been focused on the role of human herpesvirus-6
(HHV-6) in multiple sclerosis (MS) pathogenesis. However, the pathogenesis of MS  associated
with HHV-6 infection remains unknown. In this study, we measured the serum levels of
matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), and vitamin D
levels in MS patients with HHV-6 infection and MS patients without HHV-6 infection. Five
hundred sixty (including 300 females and 260 males) MS patients along with 560 healthy
subjects were analyzed for HHV-6 seropositivity using enzyme-linked immunosorbent assay
(ELISA). Subsequently, we measured the serum levels of MMP-2, MMP-9, and vitamin D levels
in  MS patients with HHV-6 infection and MS patients without HHV-6 infection by ELISA.
About 90.7% of MS patients (508/560) were seropositive for HHV-6, while 82.3% (461/560) of
healthy subjects were seropositive for this virus (p = 0.001). Moreover, there was a significant
increase in the levels of MMP-2, MMP-9, and lower vitamin D in the serum samples of MS
patients when compared with healthy subjects. Additionally, we demonstrated that the
MMP-9 levels in seropositive MS patients were significantly higher than seronegative MS
patients (p = 0.001). Finally, our results demonstrated that the mean of expanded disability
status scale (EDSS) in seropositive MS patients was significantly higher in comparison to
seronegative MS patients (p < 0.05). In conclusion, we suggest that the HHV-6 infection mayplay  a role in MS pathogenesis.
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b r a z j i n f e c t d i s .
ackground  and  objectives
S  is a neuroinflammatory disorder affecting the central ner-
ous system (CNS), demolition of the myelin sheath, and
xonal injury accompanying with diverging degrees of neuro-
ogical impairment.1 Viral infection has long been a dilemma
n the etiology of multiple sclerosis (MS) and related neu-
oinflammatory disorders. Epidemiological, pathological, and
olecular investigations in the last decades have profoundly
ssociated the human herpesvirus 6 (HHV-6) and human
erpesviruses Epstein–Barr virus (EBV) with MS.2 HHV-6 is
 neurotropic virus that frequently reactivates in immuno-
ompromised patients.3 Two variants of HHV-6 have been
ecognized: HHV-6A, with a more  prominent preference for
nfecting neural cells, and HHV-6B. However, it is less often
ssociated with disease than HHV-6B.4 HHV-6A has been
ound predominantly in MS  lesions. Primary evidence back-
ng a convincing pathogenic role for HHV-6 in MS was
ased on cerebrospinal fluid (CSF) detection of viral DNA by
olymerase chain reaction (PCR).4 Observation of viral mes-
enger RNA and protein expression in oligodendrocytes were
dditional contribution to the hypothesis of HHV-6 as an
perator of MS.5 Subsequent studies have revealed drastic
ariability in IgG- and IgM-specific responses to viruses in
SF, to viral antigens, as well as DNA detection from MS
esions.6–9
Furthermore, activation of HHV-6 and other herpes
iruses (e.g., varicella-zoster, herpes simplex viruses, and
erpesvirus-7 and 8) can trigger MS  progression. Interest-
ngly, marmosets (a small nonhuman primate) inoculated
ith HHV-6 developed an MS-like experimental neuroin-
ammatory condition when compared to controls.9,10 The
ole of vitamin D in MS  etiology draws growing attention.
he geographical distribution of the disease suggested the
nvolvement of vitamin D in disease pathogenesis.11 Several
tudies have shown that vitamin D levels are lower in MS
atients than in controls.12–16 Moreover, several studies of
5-hydroxyvitamin D levels after MS  onset have noted cor-
elations with MS  risk, progression, disability, and severity.11
MPs  are a big family of zinc-containing endopeptidases that
egenerate extracellular matrix and basement membrane
omposites (collagens, gelatin, laminin, fibronectin). Expres-
ion and activity of MMPs  are tightly controlled.17 Among of
ll MMPs, MMP-9 and MMP-2 have been extensively investi-
ated in MS  given their capacity to degenerate components
f the basal lamina and their involvement in blood-brain bar-
ier (BBB) damage.18,19 Remarkably, increasing experimental
vidence proposes the engagement of MMP-9 in the patho-
enesis of MS, since the circulating levels of MMP-9 have
een shown to be upregulated in MS  patients, in contrast
ith other noninflammatory neurological disorders (NIND)
nd healthy subjects.20–23 To investigate the roles of MMP-9,
MP-2, and vitamin D in the pathogenesis of MS associ-
ted with HHV-6 infection, we determined serum MMP-9,
MP-2, vitamin D levels, and compared them among MSatients with or without HHV-6 infection. In addition, we
ssessed HHV-6 IgG titers in MS  patients with HHV-6 infec-
ion.0;2 4(2):144–149 145
Study  design
Patient  and  sample  collection
Five hundred sixty (including 300 females and 260 males)
patients clinically diagnosed with MS  according to the diag-
nostic guidelines suggested by revised McDonald’ criteria,24
along with 560 healthy individuals (including 300 females
and 260 males) were randomly chosen. The ethical commit-
tee of the Hamadan University of Medical Science approved
(IR.UMSHA.REC.1398.409) the study. A trained neurologist
determined the expanded disability status scale (EDSS) of
patients. Inclusion criteria were: age 20–60 years, EDSS score
less than 7.0 and written informed consent of all partici-
pants. Exclusion criteria were: to be on immunosuppressant
drugs in the six months preceding study entry, and to have
complications related to vitamin D deficiency, such as rick-
ets or parathyroid diseases or use of drugs or supplements
containing vitamin D or calcium. All MS  patients had a
relapse-remitting disease course and were on IFN- treatment
(for at least two years). Of note, blood samples were taken from
all MS  patients during the remission stage of the disease. In
each study group, 5 mL  of venous blood samples were drawn
and then centrifuged to obtain a sufficient amount of serum.
Sera were quickly frozen and stored at −70 ◦C until use. In
this case-control study, we  first investigated the frequency of
HHV-6 infection in MS patients and healthy subjects (Table 1).
After defining the status of HHV-6 infection, MS patients and
healthy individuals were categorized into HHV-6 seropositive
and seronegative groups (Table 2), and the levels of MMP-2,
MMP-9, and vitamin D were evaluated in the serum of MS
patients and healthy subjects.
Enzyme-linked  immunosorbent  assay  (ELISA)  for
anti-HHV-6  IgG
The anti-HHHV-6 IgG was measured in duplicate using a com-
mercially available ELISA kit (HHV-6 IgG ELISA kit, Abnova,
Taiwan) according to the manufacturer’s instructions. Opti-
cal density (OD) was measured at 450 nm using a BioRad 650
microplate reader (BioRad Laboratories Inc, USA). HHV-6 IgG
index > 1.10 was considered as positive and less than < 0.90
negative. Intermediate index values between 0.90–1.10 were
considered equivocal and excluded from the study.
Enzyme  linked  immunosorbent  assay  (ELISA)  for  MMP-2
and MMP-9
The MMP-2 and MMP-9 were analyzed using a specific sand-
wich ELISA kit (MMP2 (ab100606) and MMP-9 (ab246539),
Abcam Inc, Cambridge, MA, USA), according to the manufac-
turer’s instructions. In brief, 100 mL  from each sample was
added to each well. Then, secondary antibodies (biotinylated)
and streptavidin labeled with horseradish peroxidase (HRP)
was added to each well. A substrate solution tetramethylben-
zidine (TMB) was applied for visualization. Optical density
content was read at 450 nm using a BioRad 650 microplate
reader. The presented data were the means of duplicate deter-
minations.
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Table 1 – Demographic and clinical features of multiple sclerosis (MS) patients and healthy subjects.
RRMS patients (n = 485) Healthy subjects (n = 485) P value
Sex (male/female) 260/300 260/300 P > 0.05
HHV-6 seropositivity 508 (236/272), 91.7% 461 (218/243), 82.3% P < 001
Age (mean ± SD) 33 ± 6.4 31 ± 7.3 P > 0.05
Disease duration (year ± SD) 5.03 ± 1.2 NA
EDSS (mean ± SD) 2.348 ± 1.45 NA
RRMS, relapsing-remitting MS; SD, standard deviation; NA, not applicable; EDSS, expanded disability status scale.
Table 2 – Four groups according to HHV-6 serostatus in multiple sclerosis (MS) patients and healthy subjects (HS).
MS HHV-6
positive (n = 52)
MS HHV-6
negative (n = 52)
HS HHV-6
positive (n = 52)
HS HHV-6
negative (n = 52)
P  value
Sex (male/female) 26/26 26/26 26/26 26/26
Age (mean ± SD) 29 ± 9.5 31 ± 7.5 33 ± 6.4 31 ± 7 P > 0.05
Disease duration (year ± SD) 4.93 ± 1.2 5.13 ± 0.8 NA NA P > 0.05
EDSS (mean ± SD) 2.508 ± 0.36 2.188 ± 0.26 NA NA P < 0.027
SS, eMS, multiple sclerosis; SD, standard deviation; NA, not applicable; ED
Chemiluminescent  immunometric  assay  for  vitamin  D
The serum levels of 25-hydroxyvitamin D were quantified
using a quantitative chemiluminescent immunometric assay
(DiaSorin, spA, Via Crescentino, Vercelli, Italy). The detec-
tion range was 4 ng/mL, and values under the limit of
detection were computed as four ng/mL. Serum levels of 25-
hydroxyvitamin D were classified into three groups: vitamin D
deficient (under 20 ng/mL); vitamin D insufficient (21 through
29 ng/mL), and normal vitamin D levels (higher than 30 ng/mL).
Statistical  analysis
Analysis of the collected data was performed using the SPSS
software version 22. Quantitative variables are described as
mean ± SD and qualitative variables as percentages. Differ-
ences between groups of variables with normal distribution
were compared using Students T-test and one-way analysis
of variance (ANOVA), followed by Tukey’s post-hoc test. In
the case of non-normality, between groups differences were
evaluated using the Kruskal-Wallis test, followed by Dunn’s
methods for pairwise checking. Graphs were depicted using
the GraphPad software version 8. The level of statistical sig-
nificance was set at p-value less than 0.05.
Fig. 1 – Comparison of anti-HHV-6 seropositivity results
between multiple sclerosis (MS) patients and healthy
subjects.xpanded disability status scale.
Results
Demographic  and  clinical  characteristics
As shown in Table 1, all participants, including relapsing
remitting multiple sclerosis (RRMS) patients and healthy indi-
viduals were age- and sex-matched. Age was not significantly
differences between groups (p > 0.05), but there were more
females in the control group (p-value less than 0.05).
Anti-HHV-6  IgG  in  MS  patients  and  healthy  subjects
A total of 91.7% of MS patients were seropositive for HHV6
versus 82.3% of healthy subjects. (p < 0.001) (Fig. 1). After
assessing HHV-6 serostatus, MS patients and healthy individ-
uals were categorized into four groups; (1) seropositive MS
patients; (2) seronegative MS  patients; (3) seropositive healthy
subjects; and (4) seronegative healthy subjects (Table 2). The
mean EDSS of MS patients was 2.348 ± 1.45 and significantly
higher in seropositive MS  patients (2.508 ± 0.36) as compared
to seronegative MS  patients (2.188 ± 0.26) (p < 0.01).
Levels  of  MMP-2  and  MMP-9  in  seropositive  and
seronegative  MS  patients
The levels of MMP-2 were significantly higher in MS  patients
as compared to healthy subjects. Moreover, MMP-2 levels in
seropositive MS patients was not different from seronega-
tive MS patients (Fig. 2). In addition, serum levels of MMP-9
was higher in MS patients compared to healthy subjects.
The MMP-9 levels were significantly higher in seropositive
MS patients when compared to seronegative MS  patients
(p < 0.0047) (Fig. 2). No association was found between serum
MMP-9 and MMP-2 levels with the EDSS (p > 0.05).Chemiluminescent  immunometric  assay
Serum of 25-hydroxyvitamin D levels in MS  patients
was significantly lower compared to healthy subjects
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ealthy subjects. MMP-2, matrix metalloproteinase-2; MMP-
ealthy subjects.
p < 0.0001) (Fig. 2). There was no significant difference in 25-
ydroxyvitamin D levels among seropositive and seronegative
S patients (p > 0.7911). Besides, there was no association
etween vitamin D levels and EDSS.
iscussion
nvironmental factors, such as viral and bacterial infections
an accelerate, aggravate, or protect patients from MS.25 The
ast majority of studies have suggested that HHV-6 is involved
n the etiology of MS. Nevertheless, this association is con-
roversial and, as is the case, experimental evidence linking
his virus to MS  is opaque.4,26 Pioneering studies describing
HV-6 viral DNA in the brains27,28 and CSF29 of MS patients
nd controls indicated that HHV-6 has strong neurotropism
hat was correlated with a CNS reservoir.27 Several clini-
al studies have proposed that MS  and episodes of disease
xacerbation are associated with concurrent viral or bacte-
ial infections.30–32 However, there is still debate regarding the
ole of HHV-6 in MS pathogenesis. In this study, we demon-
trated that the seropositivity of HHV-6 in MS patients was
ignificantly higher than healthy subjects, as was observed
n other studies.29,33–36 On the other hand, some studies
ave not shown significantly higher seropositivity rate of
HV-6 in MS  patients.36–39 Besides, a number of studies
ound no correlation between MS  and HHV-6.40–42 The hall-
arks of MS  are BBB disruption, migration of inflammatory
ells to the CNS accompanying neuroinflammation, and neu-
odegeneration. Substantial experimental evidence suggests
hat MMPs  play an active role in MS  Experimental autoim-
une encephalomyelitis pathogenesis.43 In vivo studies have
evealed that MMP-2 null mice are far more  susceptible to
xperimental autoimmune encephalomyelitis (EAE) because
f the compensatory rise in MMP-9 in these animals.44 In
AE mice, increased levels of MMP-9 favors development and
rogression of the disease, while shifts in the levels of MMP-
 have a role in its resolution.45 These data proposed that
he distinct MMPs  enzymes might have distinguished roles
n EAE development since the experiments have confirmed
hat the dual MMP-2 and MMP-9 knockout mice are resistant
o EAE progression.46 Furthermore, we  have demonstratedatrix metalloproteinase-9; MS,  multiple sclerosis; HS,
that serum levels of MMP-9 and MMP-2 in MS  patients are
significantly higher than in healthy controls. Furthermore,
seropositive MS  patients have significantly higher levels of
MMP-9, but not MMP-2, than seronegative MS  patients. Kit-
taka et al. reported a positive association between HHV-6
DNA and MMP-9/TIMP-1 levels in infants infected with HHV-
6. These researchers stated that high serum levels of MMP-9
and TIMP-1 in infants infected with HHV-6 might influence the
dysfunction of the BBB, ultimately inducing febrile seizures.47
Sanchooli et al. showed that the expression levels of CD154
isoforms, MMP-9, and MMP-2 in MS  patients are significantly
higher than in healthy subjects. Their results demonstrated
that following an exacerbation period, sCD154 concentra-
tion increases, which is mutually related to the MMPs/TIMP-1
ratio.48 Moreover, our results demonstrated that there was no
correlation between serum levels of MMP-2 and MMP-9 with
EDSS in both seropositive and seronegative MS  patients. The
vast majority of observational research has proposed a rela-
tionship between vitamin D level in serum and MS  risk, as
well as disease activity.49 We have indicated that serum lev-
els of vitamin D in MS  patients are significantly lower than
healthy subjects. Also, there were no significant differences
in vitamin D levels among seropositive and seronegative MS
patients. Besides, we observed no correlation between vita-
min  D levels and EDSS. Our results are in line with previous
studies.16,50,51
All in all, our results illustrate that the HHV-6 seropositivity
in MS patients was significantly higher than in healthy sub-
jects. In addition, MMP-9 levels and EDSS in seropositive MS
patients were markedly increased in relation to seronegative
MS patients. However, the mechanism as to how HHV-6 could
affect MS risk is uncertain, but several hypotheses have been
suggested to explain how HHV-6 may play a causative role
in MS  development, including (1) direct cytopathic effect; (2)
molecular mimicry; and (3) modulation of cytokine production
during acute infection or virus reactivation, and an increase
in an already active immune response during virus reactiva-
tion, a phenomenon also known as bystander effect. Finally,
we suggest that HHV-6 infection may play a role in MS  patho-
genesis. Further work should be undertaken to further test the
possible role of HHV-6 in MS pathogenesis.
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